PatientsVille.com Logo


PITUITARY Medical Research Studies

Up-to-date List of PITUITARY Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest PITUITARY Medical Research Studies

Rank Status Study
1 Recruiting Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
Conditions: Pituitary Adenoma;   Pituitary Tumor
Outcome Measures: Pituitary tumor enlargement;   Development of hypopituitarism;   Neurocognitive function change
2 Recruiting Characterization of Receptors in Non-functioning Pituitary Macroadenomas
Condition: Pituitary Tumor
Intervention: Other: To perform RT-PCR on the tissue obtained during surgery
Outcome Measures: To determine the expression of hormonal receptors in clinically non-functioning Pituitary macroadenomas by RT - PCR and immunohistochemistry.;   To correlate the clinical, hormonal and radiological characteristics of the patients with Pituitary tumors with the hormonal receptors status.
3 Unknown  Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress Disorder
Condition: Posttraumatic Stress Disorder
Interventions: Procedure: MRI of the Pituitary;   Procedure: DEX/CRH test
Outcome Measures: Pituitary volume;   Cortisol and ACTH levels on DEX/CRH test
4 Recruiting Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma
Condition: Pituitary Tumor
Outcome Measure:
5 Recruiting Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Conditions: Pituitary Adenomas;   Prolactinomas
Intervention: Drug: Lapatinib
Outcome Measures: Primary outcome in nonfunctioning adenomas: stabilization of tumor volume and mean tumor diameter on MRI. Stabilization is defined as < 2 mm change in any dimension. MRIs will be performed at baseline and at 3 and 6 months.;   Primary outcome in prolactinomas: normalization of prolactin levels. Prolactin levels will be measured at baseline and monthly.;   Secondary outcomes: measurement of Pituitary hormones;   Secondary outcome: visual field testing
6 Recruiting Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma
Condition: Non-functioning Pituitary Adenoma
Intervention: Drug: Pasireotide LAR
Outcome Measures: Proportion of patients with non-functioning Pituitary adenomas (NFPA) who achieve tumor volume reduction of at least 20% after 24-week treatment with pasireotide LAR;   Mean change of tumour volume assessed by Pituitary MRI;   change in tumor volume;   the effect of pasireotide LAR in hormonal response, and relevant disease-related symptoms;   Percent change of tumour volume assessed by Pituitary MRI;   Proportion of patients achieving tumour volume reduction of at least ≥ 20%
7 Recruiting Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Conditions: Acromegaly;   Gigantism;   Familial Isolated Pituitary Adenoma;   FIPA;   Pituitary Adenoma Predisposition;   PAP
Outcome Measure:
8 Recruiting Pituitary Steroid Study
Conditions: Pituitary Adenoma;   Pituitary Diseases
Interventions: Drug: hydrocortisone;   Drug: dexamethasone
Outcome Measures: Incidence of adrenal insufficiency in follow-up;   Quality of Life;   Rate of perioperative complications;   Percentage of Patients discharged on glucocorticoids
9 Unknown  Pituitary Tumor Surveillance: Pathogenic Correlation
Condition: Pituitary Tumor
Outcome Measure:
10 Not yet recruiting Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
Conditions: Pituitary Neoplasms;   Prolactinoma;   ACTH-Secreting Pituitary Adenoma;   Gigantism;   Growth Hormone-Secreting Pituitary Adenoma
Intervention: Other: Educational Intervention
Outcome Measure: The level of knowledge that patients have of their condition before and after reviewing the materials provided, and ease of use of educational materials and user satisfaction
11 Recruiting An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Conditions: Abnormalities;   Craniopharyngioma;   Cushing's Syndrome;   Endocrine Disease;   Pituitary Neoplasm
Outcome Measure:
12 Recruiting Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Conditions: Healthy;   Pituitary Disease;   Thyroid Disease
Intervention: Drug: TRH (Thyrotropin Releasing Hormone)
Outcome Measure: TSH response to TRH
13 Unknown  Expression Profile of Somatostatin Receptors and Dopamine Receptor 2 in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vivo Response to Pasireotide and Cabergoline
Conditions: Non-functioning Pituitary Adenomas;   Prolactinomas
Interventions: Drug: Pasireotide;   Drug: cabergoline
Outcome Measures: Tumor volume reduction;   Prolactin levels normalization
14 Unknown  The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor
Condition: Pituitary Adenomas
Outcome Measure:
15 Recruiting The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
Conditions: Adult Growth Hormone Deficiency;   Hypothalamic-Pituitary Disorders
Interventions: Procedure: Glucagon stimulation test and insulin tolerance test;   Procedure: glucagon stimulation test and insulin tolerance test
Outcome Measure: GST can accurately and safely diagnose adult GHD and evaluate the integrity of the HPA axis in adult patients with hypothalamic-Pituitary disorders.
16 Recruiting Proton Radiation Therapy for Pituitary Adenoma
Condition: Pituitary Adenoma
Outcome Measures: Collect and analyze outcome data on tumor control.;   Collect and analyze outcome data on normal tissue morbidity.
17 Unknown  Ante-hypophyseal Dysfunctions in Children Following Moderate to Severe Traumatic Brain Injuries
Condition: Moderate to Severe Traumatic Brain Injury
Intervention: Other: Biological and behavioral explorations
Outcome Measures: Study the link between Pituitary deficiencies highlighted at the acute phase and one year after moderate to severe TBI.;   Study the association between Pituitary deficiencies highlighted at the acute phase, 3 months and 1 year after moderate to severe TBI, globally and per deficiency category.;   Identify the other risk factors of deficiency, during the acute phase and the tardive phase i.e. signs of gravity of the TBI, type of cerebral lesion, age, lesional mechanism.;   Study the correlation between corticotropic deficiencies and post-hypophysis insufficiencies during the acute phase and the hemodynamic instability over the first 3 days after the TBI;   Compare the level and the type of behavioural and neuropsychological sequelae in children suffering from a TBI, with and without hypopituitarism.
18 Recruiting Genome-wide Association Study of Pituitary Tumors
Condition: Pituitary Adenomas
Outcome Measure:
19 Recruiting Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas
Condition: Pituitary Macroadenoma
Intervention: Radiation: Iodine Implants
Outcome Measures: Partial response (reduction in 30% of tumor volume) or greater response within 12 months from the implant procedure.;   Change of the patient's Humphrey visual field testing;   Potential toxicities associated with interstitial seed placement;   Progression free survival;   The effect of the treatment on quality of life evaluations (patient reported outcomes);   The cost-utility of the treatment arm (in terms of the primary outcome) in comparison with other widely accepted cancer and non-cancer therapies
20 Recruiting Hypothalamic-Pituitary Effects After Endoscopic Third Ventriculostomy
Condition: Obstructive Hydrocephalus
Outcome Measure: Variability of hypothalamic-Pituitary hormones after endoscopic third ventriculostomy

These studies may lead to new treatments and are adding insight into PITUITARY etiology and treatment.

A major focus of PITUITARY research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.